- Home
- HAPN vs PSNL Comparison
HAPN vs PSNL Comparison
Compare HAPN & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAPN | PSNL |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HAPN | PSNL |
|---|---|---|
| Price | $14.97 | $16.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | 33.58 |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $314,702,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $15.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.61 | $4.96 |
| 52 Week High | $21.25 | $18.89 |
Technical Indicators
Market Signals| Indicator | HAPN | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 25.43 | 50.89 |
| Support Level | N/A | $15.92 |
| Resistance Level | $21.25 | $16.39 |
| Average True Range (ATR) | 0.45 | 0.41 |
| MACD | -0.09 | -0.11 |
| Stochastic Oscillator | 14.17 | 29.24 |
Price Performance
Historical ComparisonAbout HAPN Happen Inc. Common Stock
Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.